先聲藥業(02096.HK)注射用創新藥III期臨床研究達主要終點

You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.

Hong Kong

Open Account

先聲藥業(02096.HK)注射用創新藥III期臨床研究達主要終點

阿思達克 02-24 03:40

先聲藥業(02096.HK)公布，注射用曲拉西利在接受卡鉑聯合依託泊(甘)或拓撲替康治療的廣泛期小細胞肺癌患者中的III期臨床研究達主要臨床終點。注射用曲拉西利是集團與G1合作的創新藥。2020年8月，雙方達成獨家授權合約，獲得注射用曲拉西利在大中華地區所有適應症的開發和商業化權益。

先聲藥業(02096.HK)

Relevant Stocks

先聲藥業(02096.HK)

Customer Service Hotline︰+852 3018 4526

Email︰cs@usmarthk.com

Address︰26/F, 2606, 308 Des Voeux Road Central, Sheung Wan, Hong Kong

WhatsApp︰+852 5989 2641

Join the Community：

uSmart Securities Limited

is a licensed corporation approved by the Hong Kong SFC (CE number: BJA907), provides securities trading services and is subject to its supervision.

Market News

先聲藥業(02096.HK)注射用創新藥III期臨床研究達主要終點

Services

About Us

Agreement Statement